The current valuation score of Lyell Immunopharma Inc is 7.22, ranking 250 out of 386 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.94, which is -98.59% below the recent high of -0.01 and -469.17% above the recent low of -5.34.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.